In a pivotal decision that maintains broad public access to the abortion medication mifepristone via mail, the U.S. Supreme Court has indefinitely postponed a lower court’s ruling that would have otherwise limited its distribution. This move by the high court means that patients across the United States will continue to receive the widely used abortion pill through telehealth services and subsequent mailing of the medication.
This recent decision came in the wake of an earlier directive by a federal appellate court that reinstated a rule from the Food and Drug Administration (FDA), requiring mifepristone to be dispensed in-person. However, facing potential widespread disruption and legal confusion, pharmaceutical companies Danco Laboratories and GenBioPro appealed to the Supreme Court to block this lower court ruling. These companies outlined the chaos the appellate decision had already sown among patients, healthcare providers, and pharmacies relying on the availability of the drug through less restrictive means.
Compelling their argument further was the state of Louisiana, which had previously pushed the high court to sustain the in-person dispensing requirement—a rule the FDA itself had relaxed back in 2021. Louisiana officials highlighted how the absence of this in-person regulation had enabled out-of-state providers to circumvent local abortion bans, significantly impacting the state with over a thousand medication-induced abortions attributed to these relaxed measures. It is crucial to note here that the FDA chose to remain neutral and did not voice a position on whether the mail access to mifepristone should be preserved before the Supreme Court.
The urgent grant of relief by the Supreme Court followed an individual stay issued by Justice Samuel Alito, which temporarily halted the appellate court’s decision only days before. Alito’s timely interim order preceded the full court consensus that effectively secured the continued mail distribution of mifepristone, reflecting a significant judicial action to uphold nationwide access to abortion medication despite ongoing legal challenges.
This critical case originated from a lawsuit filed by the state of Louisiana against the FDA last year, aiming to slash mail access to mifepristone nationwide, thereby impacting even states where abortion remains legal. Mifepristone, often used in conjunction with the drug misoprostol, is part of a regimen to terminate early pregnancies, a method growing in prominence with the Guttmacher Institute noting that medication-induced abortions were used in 65% of all clinician-provided abortions in 2023. More than 1.1 million abortions were reported last year with a significant number provided via telehealth in states where traditional abortion methods faced legal restrictions.
The regulation and access to mifepristone gained newfound significance following the Supreme Court’s landmark decision in 2022 to overturn Roe v. Wade, after which over half of U.S. states enacted restrictive abortion laws. Louisiana, where abortion remains tightly restricted with very few exceptions, also passed legislation in 2024 classifying both mifepristone and misoprostol as controlled substances, imposing stern penalties for their possession without prescription.
In light of the evolving judicial and legislative landscape, the Biden administration took significant steps during the COVID-19 pandemic to ease the regulatory constraints on mifepristone, suspending enforcement of the in-person dispensing rule and finding that mifepristone could be safely dispensed without requiring a physical meeting between patient and provider.
Louisiana’s lawsuit against the FDA claimed that these federal relaxations resulted in a surge of unlawful abortions within the state, allegedly bringing thousands each year and imposing substantial costs on the state through its Medicaid program. In response to this challenging scenario, a federal district court initially paused the case while the agency reviewed the safety of mifepristone—a review that typically extends well beyond a year.
While the debate concerning the safety and legality of mifepristone unfolds, pharmaceutical companies warn that prohibiting mail access would not only deprive patients of crucial, time-sensitive healthcare but also disrupt supply chains and increase health risks, particularly affecting women in rural areas or those constrained by multiple barriers to accessing in-person clinics.
Despite the broader court’s decision, Justices Thomas and Alito reflected a distinct view in their dissents. Thomas referenced the 1873 Comstock Act that prohibited mailing abortion-related materials, suggesting the drug manufacturers are not entitled to legal relief based on implications of their potentially criminal enterprise. On the other hand, Alito voiced concerns that the state’s efforts to regulate or ban abortion were significantly undermined by the continuous availability of mifepristone facilitated through these federal adjustments.
